CXCR4 and plasma cell myeloma: For instance, the therapeutic inhibition of CXCR4 (AMD3100) disrupts the interaction between myeloma cells and the BMSC, re-sensitizing myeloma cells to the PI bortezomib, leading to tumor reduction in vivo [55].